Indoco Remedies is India based Pharmaceuticals company, on February 9, reported a 178.68% rise in its consolidated net profit to Rs 253.6 million for the quarter-ended December.

The company had posted a net profit of Rs 91 million for the corresponding period of the previous fiscal.

Net sales of the company grew 17.71% to Rs 3,336.6 million for the quarter compared to Rs 2,834.5 million for the same period a year ago.

EBIDTA to net sales for the quarter is 18% at Rs 600 million, compared to 12.4% at Rs 351 million, same quarter last year.

Total expenses increased 5.74% to Rs 2,950.2 million for the quarter compared to Rs 2,790  million for the same period a year ago.

Indoco Remedies EPS has increased to Rs 2.75 in December 2020 from Rs 0.99 in December 2019.

Commenting on the third quarter FY21 results, Aditi Panandikar, Managing Director, Indoco Remedies said, "While the revenue from International business has registered a robust growth of 73%, we are yet to see revival in the Domestic business. Uptrend in EBIDTA has continued in the 3rd quarter at 18% of net sales, which is highly encouraging."

 Shares of the company gained Rs 1.65, or 0.52%, to settle at  Rs 314.55.  The total volume of shares traded  was  24,678 at the BSE (Tuesday).